


Iconovo releases Q2-2024 report
“A quarter of intense business development and constructive negotiations." says Johan Wäborg, CEO at Iconovo.
CEO MESSAGES:
STRATEGIC INITIATIVES…

Dr Orest Lastow presenting Systemic Delivery of Biologics via Inhalation: Overcoming Injection Aversion in Modern Therapies
Iconovo to present at New Updates in Drug Formulation & Bioavailability in Copenhagen August 28th. Dr Orest Lastow, CTO at Iconovo will present on…

Iconovo attends Carnegie Healthcare Webinar
Iconovo CEO Johan Wäborg gives a company presentation at Carnegie Healthcare Webinar. In the video you can hear him go through the company, the strategies…

ICONOVO AB PUBLISHES THE ANNUAL REPORT 2023 IN ENGLISH
The abbreviated annual report 2023 in English is available using the link below.
To read abbreviated Annual Report in English.

Iconovo files patent application for inhaled GLP-1 products and initiates development of new obesity treatments
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company has filed a broad patent application…

Iconovo releases Q1-2024 report
“We have made a flying start into 2024.”, says Johan Wäborg, CEO at Iconovo.
CEO's MESSAGES.
- RAMPING UP IN 2024
- ICONOVO EXPANDS BUSINESS…

Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the clinical phase I study of oxytocin in…

Iconovo to present positive data from a feasibility study on Nanofitins in ICOone
Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin based biologic drug against…

Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea
Iconovo announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce…

Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag
Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…

Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease
Iconovo has entered into an agreement to continue the formulation development with Danish rare lung disease company Kiox Pharma. This is a continuation…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se